標(biāo)題: Titlebook: Current Controversies in Bone Marrow Transplantation; Brian J. Bolwell (Director, Staff Physician) Book 2000 Humana Press Inc. 2000 blood. [打印本頁] 作者: Limbic-System 時間: 2025-3-21 16:25
書目名稱Current Controversies in Bone Marrow Transplantation影響因子(影響力)
書目名稱Current Controversies in Bone Marrow Transplantation影響因子(影響力)學(xué)科排名
書目名稱Current Controversies in Bone Marrow Transplantation網(wǎng)絡(luò)公開度
書目名稱Current Controversies in Bone Marrow Transplantation網(wǎng)絡(luò)公開度學(xué)科排名
書目名稱Current Controversies in Bone Marrow Transplantation被引頻次
書目名稱Current Controversies in Bone Marrow Transplantation被引頻次學(xué)科排名
書目名稱Current Controversies in Bone Marrow Transplantation年度引用
書目名稱Current Controversies in Bone Marrow Transplantation年度引用學(xué)科排名
書目名稱Current Controversies in Bone Marrow Transplantation讀者反饋
書目名稱Current Controversies in Bone Marrow Transplantation讀者反饋學(xué)科排名
作者: poliosis 時間: 2025-3-22 00:14 作者: 母豬 時間: 2025-3-22 00:34
Katrin Schwalenberg,Marion Jegenhe biology and heterogeneity of this disease has not yet led to significant improvement in outcome .. This chapter critically reviews present treatment results in ALL, and presents a rationale for an aggressive treatment strategy.作者: 基因組 時間: 2025-3-22 07:29 作者: 遵循的規(guī)范 時間: 2025-3-22 12:12 作者: engender 時間: 2025-3-22 14:46 作者: engender 時間: 2025-3-22 17:09 作者: 錫箔紙 時間: 2025-3-23 00:08 作者: thrombosis 時間: 2025-3-23 01:55 作者: 帶子 時間: 2025-3-23 07:14 作者: 無孔 時間: 2025-3-23 10:22 作者: 要素 時間: 2025-3-23 15:07 作者: 最低點 時間: 2025-3-23 18:54 作者: 制定 時間: 2025-3-24 00:33 作者: 條約 時間: 2025-3-24 03:14 作者: 芭蕾舞女演員 時間: 2025-3-24 07:45 作者: Bronchial-Tubes 時間: 2025-3-24 11:26 作者: 載貨清單 時間: 2025-3-24 16:33 作者: 定點 時間: 2025-3-24 22:36
Women, Gender and Oil Exploitationphology, histology, and immunophenotype (CDS., CD19., CD20., CD10., CD23.), which are now widely accepted, and increasingly recognized This lymphoma and subset of patients is more specifically defined by a distinct translocation, t(11;14)(q13;32), which results in the rearrangement of the . locus, and overexpression of cyclin D1 protein.作者: 序曲 時間: 2025-3-25 02:08 作者: 職業(yè)拳擊手 時間: 2025-3-25 05:48 作者: 愛社交 時間: 2025-3-25 11:12
What Is an Accurate Risk/Benefit Ratio for Umbilical Cord Cell Transplantation in Children and Adult depletion (TCD) has been shown to reduce acute GVHD. However, this benefit of reduced GVHD is offset by increases in the rates of graft failure, lymphoproliferative disorders associated with Epstein-Barr virus, and recurrent leukemia .,..作者: bromide 時間: 2025-3-25 13:49
Autologous Transplantation for Hodgkin’s Diseaseg this approach. These results compare favorably with historical data using conventional second-line chemoradiotherapy, and, currently, ASCT is the salvage treatment of choice for many patients with relapsed and primary refractory HD ..作者: Blasphemy 時間: 2025-3-25 16:44
Hematopoietic Stem Cell Transplantation for Mantle Cell Lymphomaphology, histology, and immunophenotype (CDS., CD19., CD20., CD10., CD23.), which are now widely accepted, and increasingly recognized This lymphoma and subset of patients is more specifically defined by a distinct translocation, t(11;14)(q13;32), which results in the rearrangement of the . locus, and overexpression of cyclin D1 protein.作者: 閑逛 時間: 2025-3-25 23:03 作者: 爵士樂 時間: 2025-3-26 01:58 作者: constitutional 時間: 2025-3-26 07:51
https://doi.org/10.1007/978-1-59259-657-7blood; bone marrow; cell; hematology; hematopoietic stem cell; hematopoietic stem cell transplantation; in作者: expository 時間: 2025-3-26 12:28
978-1-4684-9812-7Humana Press Inc. 2000作者: legacy 時間: 2025-3-26 14:24
What Is the Curative Potential of Refractory Leukemia with Related and Unrelated Allogeneic Transplaute leukemia induced complete remission (CR) in the majority of patients, but postremission therapy was inadequate to prevent relapse .. Relapsed patients, and those who failed to achieve CR, invariably died from their leukemia.作者: preeclampsia 時間: 2025-3-26 17:10 作者: APO 時間: 2025-3-27 00:55
Carmen Colitz,Fabiano Montiani-Ferreiraute leukemia induced complete remission (CR) in the majority of patients, but postremission therapy was inadequate to prevent relapse .. Relapsed patients, and those who failed to achieve CR, invariably died from their leukemia.作者: ferment 時間: 2025-3-27 03:36 作者: 主動 時間: 2025-3-27 05:58
Additional Psychocultural ThemesGenerally, eligibility includes patients less than 55, 60, or 65 yr of age. Many autologous BMT (ABMT) protocols also have age cutoffs restricting patient eligibility. The reason for such an age cutoff is presumably that the transplant procedure itself is prohibitively risky in older patients. Commo作者: 媽媽不開心 時間: 2025-3-27 09:47
Additional Psychocultural Themesowever, this approach has been limited by the availability of suitable human leukocyte antigen (HLA)-matched related donors, and by the occurrence of severe graft-vs-host disease (GVHD) when bone marrow (BM) from HLA-matched unrelated donor (MUD), or partially HLA-mismatched family member grafts, ar作者: Moderate 時間: 2025-3-27 14:36 作者: 隱藏 時間: 2025-3-27 20:42
Jong-Hwa Chun,Jang-Jun Bahk,In-Kwon Umengraftment unless the donor is syngeneic or the recipient is profoundly immunoincompetent. When BMT is performed for malignant disease, treatment of the recipient to permit engraftment is also used to eliminate residual malignancy. The ultimate success of allo-BMT for leukemia clearly depends upon 作者: mercenary 時間: 2025-3-28 01:32
Martin Torvald Hovland,Srikumar Royd to CML is 1.5/ 100,000/yr .. CML is characterized by a specific chromosomal abnormality referred to as the Philadelphia chromosome (Ph.) .,.. The Ph. results from the reciprocal translocation of the . proto-oncogene on the long arm of chromosome 9 (g34.1) to the 5.8 kb breakpoint cluster region (b作者: 殖民地 時間: 2025-3-28 03:45 作者: Blasphemy 時間: 2025-3-28 10:01 作者: 災(zāi)禍 時間: 2025-3-28 11:48
Heritability of Aggressive Behavior,of the eradication of leukemia by high-dose chemotherapy (CT), stem cells previously collected, either in remission or at time of active disease, will almost certainly be contaminated by a population of tumor cells. Viable cells will logically result in relapse. If, however, there are no viable tumo作者: 饒舌的人 時間: 2025-3-28 14:57 作者: Scintillations 時間: 2025-3-28 20:26 作者: 藐視 時間: 2025-3-29 01:05
Petter Gottschalk,Christopher Hamertoneripheral blood progenitor cell transplantation (PBPCT) over the past two decades. The use of ABMT in non-Hodgkin’s lymphoma (NHL) is an unequivocal success. AMBT now represents state-of-the-art care for many lymphoma patients, and has changed the standard of care for such patients worldwide. In the作者: 宮殿般 時間: 2025-3-29 06:21 作者: 時代錯誤 時間: 2025-3-29 08:46
,Conclusion: Why It Didn’t Happen Here,cades. Despite expanding knowledge of genetics, prognostic factors, and biology, as well as advances in surgical management, adjuvant chemotherapy (CT), and radiotherapy, many women will die from progressive, metastatic breast cancer (MBC). Over the past 10 yr, many investigators have studied the ro作者: Obsequious 時間: 2025-3-29 14:56 作者: arbiter 時間: 2025-3-29 16:37
Worldviews, Ethics and Organizational Lifey curable, particularly when discovered early, stage at presentation is the predominant factor in determining outcome and treatment. Fortunately, even patients who present with disseminated disease can be cured with cisplatin-based combination chemotherapy (CT) and aggressive surgical extirpation of作者: 酷熱 時間: 2025-3-29 21:06 作者: adroit 時間: 2025-3-30 00:05 作者: 施魔法 時間: 2025-3-30 06:43
Is Autologous Transplantation for Non-Hodgkin’s Lymphoma Underutilized?ntional-dose CT, and cure some patients who are otherwise incurable. With current techniques utilizing hematopoietic growth factors and PBPCs, mortality risks have decreased to 1–3%. The well-documented efficacy, coupled with decreased morbidity and mortality, have led to clinical research studies u作者: consent 時間: 2025-3-30 09:51
High-Dose Chemotherapy with Stem Cell Rescue for Germ Cell CancerT) with hematopoietic stem cell rescue (HSCR) has been attempted, with varying degrees of success. This chapter examines these various settings and the trials, which have been performed to alter the otherwise dismal course of these patients.作者: 臭名昭著 時間: 2025-3-30 14:21 作者: 曲解 時間: 2025-3-30 17:50 作者: Aesthete 時間: 2025-3-30 23:34
